NAD+ & mitochondrial peptides
Mitochondrial research is the fastest-growing branch of the longevity field. This guide covers the NAD+ cofactor itself and three pharmacologically distinct ways researchers raise mitochondrial bioenergetic capacity in cell and animal models: precursor loading (NAD+ / NMN / NR), mitochondrial-derived peptides (MOTS-c, Humanin), and direct mitochondrial modulators (SLU-PP-332, 5-amino-1MQ).
What NAD+ actually does
Nicotinamide adenine dinucleotide is a coenzyme that shuttles electrons between catabolic and biosynthetic reactions throughout the cell. It exists in oxidized (NAD+) and reduced (NADH) forms. The NAD+/NADH ratio drives oxidative phosphorylation in the mitochondrial electron transport chain, and NAD+ is the obligate substrate for three families of regulatory enzymes:
- Sirtuins (SIRT1–SIRT7) — NAD+-dependent deacetylases that regulate metabolic and stress-response gene programs.
- PARPs — consume NAD+ during DNA-damage repair.
- CD38 — surface NADase whose activity rises with age and depletes the NAD+ pool.
Tissue NAD+ levels decline with age. Raising NAD+ in research models has been associated with mitochondrial-biogenesis markers, improved insulin sensitivity, and extended healthspan in rodent studies.
NAD+ vs NMN vs NR — three ways to raise the pool
| Molecule | What it is | Route | Notes |
|---|---|---|---|
| NAD+ | Full cofactor (664 Da) | Subcutaneous / IV | Bypasses oral salvage; injection-site sensitivity is common |
| NMN (nicotinamide mononucleotide) | One-step precursor | Oral / sublingual / SC | Converted to NAD+ via NMNAT enzymes inside cells |
| NR (nicotinamide riboside) | Two-step precursor | Oral | Phosphorylated to NMN first, then to NAD+ |
Research interest has shifted toward injectable NAD+ and NMN because oral bioavailability of the larger precursors is limited by gut conversion to nicotinamide.
Mitochondrial-derived peptides (MDPs)
MDPs are short peptides encoded within mitochondrial DNA itself — a discovery from the last 15 years that overturned the assumption that mtDNA only codes for OXPHOS components. The two most-studied MDPs in research are:
- MOTS-c (mitochondrial open reading frame of the 12S rRNA-c, 16 aa) — modulates AMPK signaling, improves glucose disposal and insulin sensitivity in animal models, levels decline with age.
- Humanin (24 aa) — cytoprotective peptide that inhibits apoptosis via BAX binding and modulates the IGF-1 axis; studied in neuronal and metabolic models.
Both peptides are administered subcutaneously in research; typical study doses are 2–10 mg per session, 2–3× weekly.
Direct mitochondrial modulators (non-peptide)
- SLU-PP-332 — small-molecule pan-ERR (estrogen-related receptor) agonist. ERRα/β/γ are transcription factors that drive mitochondrial biogenesis and oxidative-metabolism gene programs. Research models show increased exercise capacity and shifts in muscle fiber-type composition.
- 5-amino-1MQ — nicotinamide N-methyltransferase (NNMT) inhibitor. NNMT depletes the cellular methyl-donor pool and consumes NAD+ precursors. Inhibiting NNMT in adipocytes increases energy expenditure in animal models.
- L-carnitine — shuttles long-chain fatty acids into the mitochondrial matrix for β-oxidation. Often co-studied with NAD+ protocols.
These are not peptides — they're small molecules that act on the same biology — and we've grouped them here because they're studied in the same mitochondrial-bioenergetic context.
Reconstitution and storage
NAD+ in particular is more oxidation-sensitive than most peptides; keep reconstituted vials wrapped from light and use within 14–21 days at 2–8 °C. MOTS-c, Humanin, and the small molecules follow standard cold-chain rules — see the storage & handling guide for the protocol and the dosage protocols guide for per-vial reconstitution math.
Safety, risks & legal notice
Read before ordering or conducting any research
For laboratory research only
Every compound described on this page is sold and provided strictly as a research-grade reagent for in-vitro and animal-model studies. These products are not intended for human consumption, cosmetic use, dietary supplementation, or any clinical or therapeutic application. By purchasing, you represent that you are a qualified researcher, laboratory, or educational institution with appropriate facilities and oversight.
Not FDA-approved or evaluated
None of the compounds on this page have been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or equivalent bodies for the indications discussed in research contexts. Safety and efficacy profiles in humans are unknown, incompletely characterized, or based solely on pre-clinical and investigator-initiated studies.
No medical, clinical, or dosing advice
Dr Jays Peptides does not employ physicians, pharmacists, or clinical researchers. Nothing on this page — including dosage figures, reconstitution math, or mechanism descriptions — constitutes medical advice, a prescribing recommendation, or instructions for self-administration. If you are considering any peptide for personal use, consult a licensed healthcare provider who can evaluate your individual risk factors, medication interactions, and monitoring needs.
Class-specific risk signals
- NAD+ injection-site reactions: subcutaneous and IV NAD+ frequently cause flushing, warmth, pruritus, and nausea at higher infusion rates. These are histamine-mediated and dose-rate dependent, not allergic per se, but can be distressing to research subjects.
- Methylation depletion (NNMT inhibitors): 5-amino-1MQ and related NNMT inhibitors raise SAM/SAH ratios in theory, but chronic use may perturb one-carbon metabolism. No long-term safety data exists.
- Mitochondrial overload: forcing mitochondrial biogenesis beyond a cell's antioxidant capacity could theoretically increase ROS production. Co-administration with antioxidant protocols is an active research question, not a settled safety practice.
- Lack of long-term human data: MOTS-c, Humanin, SLU-PP-332, and 5-amino-1MQ have no Phase III safety databases. Duration-limited exposure in animal models is the extent of published safety characterization.
- Drug interactions: NAD+ precursors may interact with chemotherapy regimens (some of which are NAD+ depletion–dependent). Any oncology research context requires specialist oversight.
General risk factors
- Purity and contamination: Research peptides are not manufactured to pharmaceutical-grade GMP standards. Even high-purity lots may contain trace endotoxins, residual solvents, or unrelated peptide sequences.
- Stability and degradation: Improper storage, repeated freeze–thaw cycles, or use beyond recommended reconstitution windows can produce degraded products with unknown toxicology.
- Immunogenicity: Foreign peptides can elicit antibody responses; repeated administration may cause allergic reactions or neutralizing antibodies that alter pharmacokinetics in unpredictable ways.
- Drug interactions: Peptides may potentiate or antagonize prescription medications, herbal supplements, or other research compounds. No systematic interaction data exists for most of these molecules.
- Pregnancy, lactation, and pediatric populations: Zero safety data. Absolute contraindication for use in these populations.
Legal status & buyer responsibility
The legal status of research peptides varies by country, state, and municipality. It is the buyer's sole responsibility to understand and comply with all applicable laws, regulations, and institutional policies in their jurisdiction before ordering. Dr Jays Peptides ships products with accurate customs declarations; buyers are responsible for any import duties, inspections, or seizures. We reserve the right to cancel any order where we believe the buyer lacks legitimate research intent or where shipment would violate local law.
Limitation of liability: To the maximum extent permitted by law, Dr Jays Peptides and its affiliates, suppliers, and agents disclaim all liability for any injury, illness, adverse reaction, or loss arising from the purchase, handling, or use of any product described on this page. This includes liability for negligence, product defect, mislabeling, or failure to warn. By proceeding with a purchase, you agree to indemnify and hold harmless Dr Jays Peptides from any claims, damages, or expenses related to your research activities.